Proteomics of Bacterial Pathogens

Phillip Cash

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Significant progress has been made in the characterisation of bacterial pathogens using a combination of genomic and proteomic technologies. The data generated have improved our understanding of how these microbes interact with the human host to cause disease. Objective: Practical outcomes include the identification of putative vaccines and new drug targets. Method: This review highlights those developments achieved through the use of proteomic technologies including established electrophoretic methods as well as state-of-the-art mass spectrometry based techniques. Conclusion: Proteomics has been used at diverse levels to investigate microbial physiology, gene expression and the complex interactions between bacteria and their hosts. Pathogenic determinants are identified through comparative proteomics between virulent and avirulent isolates whereas complex disease phenotypes can be correlated with specific proteomic signatures identified through the analysis of large collections of natural isolates. Initial progress has been achieved on defining the bacterial proteome during in vivo infection, which will probably be a key research area over the coming years.

Original languageEnglish
Pages (from-to)461-473
Number of pages12
JournalExpert Opinion on Drug Discovery
Volume3
Issue number5
DOIs
Publication statusPublished - May 2008

Keywords

  • bacteria
  • pathogenesis
  • protein
  • proteomics
  • vaccine and antibiotic development
  • 2-dimensional gel-electrophoresis
  • Mycobacterium-Bovis BCG
  • resistant Staphylococcus-Aureus
  • flight mass-spectrometry
  • immobilized PH gradients
  • helicobacter-pylori
  • Escherichia-Coli
  • Pseudomonas-Aeruginosa
  • Neisseria-Gonorrhoeae
  • membrane subproteome

Cite this

Proteomics of Bacterial Pathogens. / Cash, Phillip.

In: Expert Opinion on Drug Discovery, Vol. 3, No. 5, 05.2008, p. 461-473.

Research output: Contribution to journalArticle

Cash, Phillip. / Proteomics of Bacterial Pathogens. In: Expert Opinion on Drug Discovery. 2008 ; Vol. 3, No. 5. pp. 461-473.
@article{e97b2d1300f04c4d92ddddb074b1a26e,
title = "Proteomics of Bacterial Pathogens",
abstract = "Background: Significant progress has been made in the characterisation of bacterial pathogens using a combination of genomic and proteomic technologies. The data generated have improved our understanding of how these microbes interact with the human host to cause disease. Objective: Practical outcomes include the identification of putative vaccines and new drug targets. Method: This review highlights those developments achieved through the use of proteomic technologies including established electrophoretic methods as well as state-of-the-art mass spectrometry based techniques. Conclusion: Proteomics has been used at diverse levels to investigate microbial physiology, gene expression and the complex interactions between bacteria and their hosts. Pathogenic determinants are identified through comparative proteomics between virulent and avirulent isolates whereas complex disease phenotypes can be correlated with specific proteomic signatures identified through the analysis of large collections of natural isolates. Initial progress has been achieved on defining the bacterial proteome during in vivo infection, which will probably be a key research area over the coming years.",
keywords = "bacteria, pathogenesis, protein, proteomics, vaccine and antibiotic development, 2-dimensional gel-electrophoresis, Mycobacterium-Bovis BCG, resistant Staphylococcus-Aureus, flight mass-spectrometry, immobilized PH gradients, helicobacter-pylori, Escherichia-Coli, Pseudomonas-Aeruginosa, Neisseria-Gonorrhoeae, membrane subproteome",
author = "Phillip Cash",
year = "2008",
month = "5",
doi = "10.1517/17460441.3.5.461",
language = "English",
volume = "3",
pages = "461--473",
journal = "Expert Opinion on Drug Discovery",
issn = "1746-0441",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Proteomics of Bacterial Pathogens

AU - Cash, Phillip

PY - 2008/5

Y1 - 2008/5

N2 - Background: Significant progress has been made in the characterisation of bacterial pathogens using a combination of genomic and proteomic technologies. The data generated have improved our understanding of how these microbes interact with the human host to cause disease. Objective: Practical outcomes include the identification of putative vaccines and new drug targets. Method: This review highlights those developments achieved through the use of proteomic technologies including established electrophoretic methods as well as state-of-the-art mass spectrometry based techniques. Conclusion: Proteomics has been used at diverse levels to investigate microbial physiology, gene expression and the complex interactions between bacteria and their hosts. Pathogenic determinants are identified through comparative proteomics between virulent and avirulent isolates whereas complex disease phenotypes can be correlated with specific proteomic signatures identified through the analysis of large collections of natural isolates. Initial progress has been achieved on defining the bacterial proteome during in vivo infection, which will probably be a key research area over the coming years.

AB - Background: Significant progress has been made in the characterisation of bacterial pathogens using a combination of genomic and proteomic technologies. The data generated have improved our understanding of how these microbes interact with the human host to cause disease. Objective: Practical outcomes include the identification of putative vaccines and new drug targets. Method: This review highlights those developments achieved through the use of proteomic technologies including established electrophoretic methods as well as state-of-the-art mass spectrometry based techniques. Conclusion: Proteomics has been used at diverse levels to investigate microbial physiology, gene expression and the complex interactions between bacteria and their hosts. Pathogenic determinants are identified through comparative proteomics between virulent and avirulent isolates whereas complex disease phenotypes can be correlated with specific proteomic signatures identified through the analysis of large collections of natural isolates. Initial progress has been achieved on defining the bacterial proteome during in vivo infection, which will probably be a key research area over the coming years.

KW - bacteria

KW - pathogenesis

KW - protein

KW - proteomics

KW - vaccine and antibiotic development

KW - 2-dimensional gel-electrophoresis

KW - Mycobacterium-Bovis BCG

KW - resistant Staphylococcus-Aureus

KW - flight mass-spectrometry

KW - immobilized PH gradients

KW - helicobacter-pylori

KW - Escherichia-Coli

KW - Pseudomonas-Aeruginosa

KW - Neisseria-Gonorrhoeae

KW - membrane subproteome

U2 - 10.1517/17460441.3.5.461

DO - 10.1517/17460441.3.5.461

M3 - Article

VL - 3

SP - 461

EP - 473

JO - Expert Opinion on Drug Discovery

JF - Expert Opinion on Drug Discovery

SN - 1746-0441

IS - 5

ER -